DISA LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 197501110N)
(the "**Company**")

MINUTES OF THE ANNUAL GENERAL MEETING ("AGM" OR "MEETING") OF THE COMPANY

PLACE	:	2 Bukit Merah Central, Podium Block, Level 3, Room P301, Singapore 159835	
DATE	:	Tuesday, 27 October 2026	
TIME	:	10:00 a.m.	
PRESENT	:	Mr. Chng Weng Wah	- Executive Chairman, Managing Director and Chief Executive Officer
		Mr. Lim Soon Hock	- Lead Independent Director
		Mr. Low Yeow Boon	- Non-Executive Independent Director
		Mr. George Kho Wee Hong	- Non-Executive and Non-Independent Director
IN ATTENDANCE	:	As set out in the attendance list annexed hereto	
CHAIRMAN OF THE MEETING	:	Mr. Chng Weng Wah	

I. OPENING

Mr. Chng Weng Wah, Executive Chairman, Managing Director and Chief Executive Officer of the Company (the "**Chairman**") welcomed shareholders to the AGM of the Company.

II. CALL TO ORDER AND QUORUM

The Chairman called the AGM to order at 10:00 a.m. and he introduced the members of the Board present at the AGM to the shareholders. The Company Secretary confirmed that a quorum was present for the AGM.

III. NOTICE

The Notice of the Meeting dated 12 October 2026 was taken as read.

As stated in the notice of AGM, shareholders were given the opportunity to ask questions by submitting their questions in advance of the AGM. There were no questions received from shareholders by the stipulated deadline. The Chairman informed the shareholders present that they can raise questions during the AGM.

IV. VOTING

The Chairman informed that all resolutions tabled at the Meeting would be voted by poll in accordance with the Rule 730A(2) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") (the "**Catalist Rules**").

The Chairman informed the Meeting that some shareholders had appointed the Chairman of the Meeting as their proxy at the Meeting, and that he, as the Chairman of the Meeting, would vote in accordance with the instructions of the said shareholders.

He further informed that the Company had appointed Convene SG Pte. Ltd. and Complete Corporate Services Pte. Ltd. as the polling agent and scrutineer of the AGM, respectively. The poll voting results would be shown after the scrutineer has verified the votes casted.

ORDINARY BUSINESS

1. ORDINARY RESOLUTION 1
DIRECTORS' STATEMENT, AUDITED FINANCIAL STATEMENTS TOGETHER WITH AUDITOR'S REPORT

Resolution 1 was to receive and adopt the Directors' Statement and Audited Financial Statements for the financial year ended 30 June 2026 and the Auditor's Report thereon.

Ms. Wong Lem Eng ("**Vivian**") proposed and Mr. Mohammad Azri Bin Razali ("**Azri**") seconded the motion to table resolution 1.

The shareholders present were asked whether they had any questions on this item.

Shareholder 1 sought an update on the Company's Single-Scan Serialization ("**3S Smart Barcode**"), a solution that helps the retailer to prevent invalid and fraudulent returns. The Chairman responded that introducing new products to established market participants typically require considerable time and effort. He assured that the Company was actively working towards building and expanding the product's presence in the United States of America.

Shareholder 1 noted that the Company's business activities appear to be pivoting towards the healthcare sector and he queried whether the proprietary software product would risk becoming obsolete in view of rapid pace of technology advancements. Mr. Lim Soon Hock ("**Mr. Lim**") shared the Company's enthusiasm for the commercial potential of the 3S Smart Barcode. He further assured shareholders of the Chairman's hard work and dedication in leading the Company through its final development milestones. Mr. Lim concurred with the Chairman's earlier point that some opportunities may require a longer time to commercialize. He explained that the Company had remained committed to the development of the 3S Smart Barcode as it believed in its commercial potential, not only within the retail sector but also in other industries. With regards to the Company's venture into the healthcare sector, Mr. Lim informed that the Company was currently exploring several opportunities which, if successfully pursued, could provide the Group with additional revenue streams.

The Chairman added that even though the current year's financials reflected a loss, he viewed this as an investment to nurture and grow the business and hoped that shareholders would take a longer-term view as the Company works towards creating sustainable value.

Shareholder 1 further enquired whether the Company intends to raise funds or undertake any share consolidation exercise to improve the Company's share price. The Chairman explained that the liquidity and trading performance of the Company's shares were not within the Company's control. He added that a share consolidation exercise would involve various factors and considerations, and that the Company was therefore unable to provide a definitive view on whether such an exercise would be undertaken.

As there were no further questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 1.

The results of Ordinary Resolution 1 tabled at the Meeting, taken on a poll, were as follows:

Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
3,901,939,990	3,898,549,990	99.91	3,390,000	0.09

Based on the above result, the Chairman declared Ordinary Resolution 1 carried.

It was **RESOLVED** as an ordinary resolution –

That the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 30 June 2026 together with the Auditors' Report thereon be received and adopted.

2. ORDINARY RESOLUTION 2
PAYMENT OF DIRECTORS' FEES FOR THE FINANCIAL YEAR ENDED 30 JUNE 2026

Resolution 2 dealt with the payment of Directors' fees of S$107,100 for the financial year ended 30 June 2026.

Ms. Koh Hwee Li ("**Helen**") proposed and Vivian seconded the motion to table resolution 2.

The shareholders present were asked whether they had any questions on this item.

Shareholder 2 enquired how the remuneration of Directors was determined and the basis on which Directors' fees were assessed. Mr. Low Yeow Boon ("**Mr. Low**") responded that an assessment of each Director's contribution and performance was conducted at the end of each financial year. Based on the assessment, the Company would determine the proposed Directors' fees, which would then be put forth for shareholders' approval at the AGM. He added that the Company's remuneration structure was also benchmarked against prevailing market practices.

Shareholder 2 asked about the Company's outlook for the coming financial year and the efforts of the Directors, particularly the Non-Executive Directors, towards the Company's improved performance. Mr. Lim explained that the Board's responsibilities extend beyond overseeing the Company's financial performance, encompassing other important areas such as upholding high standards of corporate governance and ensuring that the Company's businesses are conducted ethically.

As there were no further questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 2.

The results of Ordinary Resolution 2 tabled at the Meeting, taken on a poll, were as follows:

Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)

3,905,614,990	3,900,049,990	99.86	5,565,000	0.14

Based on the above result, the Chairman declared Ordinary Resolution 2 carried.

It was **RESOLVED** as an ordinary resolution –

That the Directors' fees of S$107,100 for the financial year ended 30 June 2026 be paid quarterly in arrears.

3. ORDINARY RESOLUTION 3
RE-ELECTION OF MR. LIM SOON HOCK AS A DIRECTOR

Resolution 3 dealt with the re-election of Mr. Lim Soon Hock ("**Mr. Lim**") as a Director of the Company.

Mr. Chng informed that Mr. Lim would retire by rotation as a Director of the Company pursuant to Regulation 92 of the Company's Constitution at this AGM and being eligible, he has offered himself for re-election.

Mr. Chng further informed that Mr. Lim has served on the Board of Directors of the Company for an aggregate period of more than nine (9) years from the date of his appointment on 11 May 2017. Pursuant to Rule 406(3)(d)(iv) of the Catalist Rules, a director will not be independent if he has been a director of the issuer for an aggregate period of more than nine (9) years. Accordingly, Mr. Lim would not be considered independent upon the conclusion of this AGM.

Mr. Lim would, upon re-appointment as a Director of the Company, be re-designated as a Non-Executive and Non-Independent Chairman and step down as the Lead Independent Director and the Chairman of the Nominating Committee ("**NC**") of the Company. He would remain a member of the Audit and Risk Management Committee ("**AMRC**"), the Remuneration Committee ("**RC**"), and the NC of the Company. The Board considered Mr. Lim to be non-independent for the purpose of Rule 704(7) of the Catalist Rules.

Azri proposed and Helen seconded the motion to table resolution 3.

The shareholders present were asked whether they had any questions on this item.

Shareholder 2 asked whether Mr. Lim is related to Soon Hock Group, to which Mr. Lim responded that he is not related to the entity in any manner. Mr. Low explained that the Board had decided, for good corporate governance, to have different individuals to take on the role of the Chairman and the Chief Executive Officer of the Company. Accordingly, upon Mr. Lim's re-designation as the Non-Executive and Non-Independent Chairman, Mr. Chng Weng Wah will step down as the Executive Chairman of the Company. Mr. Lim expressed his appreciation for the opportunity to serve as Chairman of the Board and committed to executing his duties to the best of his ability.

Shareholder 1 enquired if the Board intended to appoint a Director with medical expertise, given the Company's strategic pivot into the healthcare sector. The Chairman clarified that medical and clinical governance matters would be managed at the entity and operational level rather than at the Board level. The Chairman further highlighted that the Group is supported by a Chief Scientist with a healthcare background and a medical practitioner. Mr. Lim added that he had over two (2) decades of experience in chairing committees in the healthcare sector and is an investor of overseas hospital chains. He assured shareholders that the Group has access to relevant healthcare expertise to support its strategic direction in the healthcare sector and that the Board is not entirely without healthcare-related expertise.

Shareholder 1 emphasised the importance of the Board establishing clear strategic directions for the Company. Mr. Lim agreed, noting that the Directors devote considerable time during board meetings to deliberating on the Company's strategic direction. The Chairman outlined the key strategic initiatives being pursued by the Group with the Board's support, including the operationalization of Advanced Digital Healthcare Pte. Ltd. and Digital Life Line Pte. Ltd., as well as the development of the 3S Smart Barcode. Mr. George Kho Wee Hong ("**Mr. Kho**") also concurred on the importance of having clear strategic directions and assured shareholders that the Board remains prudent and deliberate in its decision-making processes, with due consideration given to the Company's long-term interests and objectives.

As there were no further questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 3.

The results of Ordinary Resolution 3 tabled at the Meeting, taken on a poll, were as follows:

Total number of shares represented by votes for and against the relevant resolution	**FOR**		**AGAINST**	
	Number of shares	**As a percentage of total number of votes for and against the resolution (%)**	**Number of shares**	**As a percentage of total number of votes for and against the resolution (%)**
3,901,939,990	3,901,549,990	99.99	390,000	0.01

Based on the above result, the Mr. Chng declared Ordinary Resolution 3 was carried.

It was **RESOLVED** as an ordinary resolution –

THAT Mr. Lim Soon Hock, retiring by rotation pursuant to Regulation 92 of the Constitution of the Company, be and is hereby re-elected as a Director of the Company.

It was further noted –

THAT Mr. Lim Soon Hock would be re-designated as a Non-Executive and Non-Independent Chairman and step down as the Lead Independent Director and the Chairman of the NC of the Company. He will remain a member of the ARMC, the RC, and the NC of the Company.

4. ORDINARY RESOLUTION 4
RE-APPOINTMENT OF AUDITORS

The Chairman informed that next motion was the re-appointment of Messrs Baker Tilly TFW LLP as Auditors of the Company and authorising the Directors of the Company to fix their remuneration.

Vivian proposed and Azri seconded the motion to table resolution 4.

The shareholders present were asked whether they had any questions on this item. As there were no questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 4.

The results of Ordinary Resolution 4 tabled at the Meeting, taken on a poll, were as follows:

Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
3,903,439,990	3,903,049,990	99.99	390,000	0.01

Based on the above result, the Chairman declared Ordinary Resolution 4 carried.

It was **RESOLVED** as an ordinary resolution –

That Messrs Baker Tilly TFW LLP be and are hereby appointed as the Independent Auditors of the Company until the conclusion of the next annual general meeting, and the Directors be and are hereby authorized to fix their remuneration.

5. ANY OTHER ORDINARY BUSINESS

As no notice of any other ordinary business was received by the Company, the Meeting proceeded to deal with the special business of the Meeting.

SPECIAL BUSINESS

6. ORDINARY RESOLUTION 5
AUTHORITY TO ALLOT AND ISSUE SHARES AND/OR OTHER INSTRUMENTS

The Chairman informed that Resolution 5 was to seek shareholders' approval to empower the Directors to allot and issue shares in the capital of the Company and to make or grant new instruments (such as warrants or debentures) convertible into shares, and to issue shares in pursuance of such instruments.

Helen proposed and Azri seconded the motion to table resolution 5.

The shareholders present were asked whether they had any questions on this item.

Shareholder 2 enquired on the number and type of shares that the Company intended to issue under this proposed resolution. The Chairman explained that the mandate was sought to provide the Company with flexibility to raise funds through the allotment and issuance of new shares to meet its funding needs, subject to the limits and conditions set out in the proposed resolution.

Shareholder 3 requested an update regarding the warrants announced by the Company in 2025. The Chairman clarified that the warrants will expire on 18 December 2026, following which any unexercised warrants would lapse and cease to be valid. He added that warrant holders may exercise their warrants prior to the expiry date, subject to prevailing market conditions and share price. He further assured that the Company would make timely announcements on its financial results and material business developments, as and when required, to keep shareholders informed and provide them with the necessary information to make well-informed investment decisions.

As there were no further questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 5.

The result of Ordinary Resolution 5 tabled at the Meeting, taken on a poll, was as follows:

Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
3,902,439,990	3,902,049,990	99.99	390,000	0.01

Based on the above result, the Chairman declared Ordinary Resolution 5 carried.

It was **RESOLVED** as an ordinary resolution –

That pursuant to Section 161 of the Companies Act, 1967 of Singapore ("**Companies Act**") and Rule 806 of the Catalist Rules, authority be and is hereby given to the Directors of the Company to:

(A) (i) allot and issue shares in the capital of the Company ("**Shares**") whether by way of rights, bonus or otherwise; and/or

(ii) make or grant offers, agreements or options (collectively, "**Instruments**") that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustment to) options, warrants, debentures or other instruments convertible into Shares,

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and

(B) (notwithstanding that the authority conferred by this Ordinary Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors while this Ordinary Resolution was in force,

provided that:

(a) the aggregate number of Shares to be issued pursuant to this Ordinary Resolution (including Shares to be issued in pursuance of Instruments made or granted pursuant to this Ordinary Resolution) does not exceed 100% of the total number of issued Shares in the capital of the Company (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (b) below), of which the aggregate number of Shares to be issued other than on a pro rata basis to shareholders of the Company (including Shares to be issued in pursuance of Instruments made or granted pursuant to this Ordinary Resolution) does not exceed 50% of the total number of issued Shares in the capital of the Company (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (b) below);

(b) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (a) above, the percentage of the total issued Shares shall be based on the total number of issued Shares in the capital of the Company (excluding treasury shares and subsidiary holdings) at the time of passing of this Ordinary Resolution, after adjusting for:

(i) new Shares arising from the conversion or exercise of any convertible securities;

(ii) new Shares arising from exercise of share options or vesting of share awards, provided the share options or share awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and

(iii) any subsequent bonus issue, consolidation or subdivision of Shares.

Adjustments in accordance with sub-paragraphs (b)(i) and (b)(ii) above are only to be made in respect of new Shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Ordinary Resolution;

(c) in exercising the authority conferred by this Ordinary Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), all applicable legal requirements under the Companies Act and the Company's Constitution for the time being; and

(d) (unless revoked or varied by the Company in a general meeting) the authority conferred by this Ordinary Resolution shall continue in force (i) until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law and the Catalist Rules to be held, whichever is the earlier; or (ii) in the case of Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Ordinary Resolution, until the issuance of such Shares in accordance with the terms of the Instruments.

7. ORDINARY RESOLUTION 6
AUTHORITY TO ISSUE SHARES UNDER THE DISA EMPLOYEE SHARE OPTION SCHEME 2010, DISA EMPLOYEE SHARE OPTION SCHEME 2021 (THE "DISA ESOS 2010 AND 2021") AND DISA PERFORMANCE SHARES SCHEME (THE "DISA PS SCHEME")

The Chairman informed that Resolution 6 was to seek shareholders' approval to authorise the Directors to offer and grant share options and share awards in accordance with the provisions of DISA ESOS 2021 and DISA PS Scheme, provided always that the aggregate number of new Shares to be allotted and issued pursuant to DISA ESOS 2010, DISA ESOS 2021 and DISA PS Scheme and any other share schemes implemented or to be implemented by the Company shall not exceed 15% of the Company's total number of issued shares (excluding treasury shares and subsidiary holdings).

Azri proposed and Helen seconded the motion to table resolution 6.

The shareholders present were asked whether they had any questions on this item.

Shareholder 2 enquired about the number of share options issued so far under the Company's share schemes. Ms. Wong Ah Kiow ("**Ms. Wong**"), Chief Financial Officer of the Company, responded that an aggregate of 928,000,000 share options, representing approximately 6.55% of the Company's total issued share capital, had been granted thus far as incentive to retain the Company's key staff.

Shareholder 2 further enquired if the grant of the share options was performance-based. In response, the Chairman confirmed that the share options were granted based on performance and contributions. He added that the share options granted to employees would be forfeited upon their resignation, thereby reinforcing the Company's efforts to retain key personnel. Mr. Lim clarified that the Company's share schemes align with standard market practices adopted by many public listed companies. Mr. Low further explained that the grant of share options formed an integral part of the Company's staff retention strategy, aimed at

incentivizing and retaining key personnel to support the Company's ongoing operations and business objectives. He emphasized that this initiative was driven by the Company's internal staff retention goals rather than prevailing market conditions.

As there were no further questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 6.

The result of Ordinary Resolution 6 tabled at the Meeting, taken on a poll, was as follows:

Total number of shares represented by votes for and against the relevant resolution	**FOR**		**AGAINST**	
	Number of shares	**As a percentage of total number of votes for and against the resolution (%)**	**Number of shares**	**As a percentage of total number of votes for and against the resolution (%)**
3,900,439,990	3,898,549,990	99.95	1,890,000	0.05

Based on the above result, the Chairman declared Ordinary Resolution 6 carried.

It was **RESOLVED** as an ordinary resolution –

That pursuant to Section 161 of the Companies Act, authority be and is hereby given to the Directors of the Company to offer and grant share options and share awards in accordance with the provisions of the DISA ESOS 2021 and DISA PS Scheme and to allot and issue from time to time such number of Shares in the capital of the Company as may be required to be issued pursuant to the exercise of options under the DISA ESOS 2010 and DISA ESOS 2021, and the vesting of share awards under the DISA PS Scheme, whether granted during the subsistence of this authority or otherwise, provided always that the aggregate number of new Shares to be allotted and issued pursuant to the DISA ESOS 2010, DISA ESOS 2021 and DISA PS Scheme and any other share schemes implemented or to be implemented by the Company, shall not exceed 15% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company from time to time and such authority shall, unless revoked or varied by the Company in a general meeting, continue to be in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law and the Catalist Rules to be held, whichever is earlier.

8. ORDINARY RESOLUTION 7
THE PROPOSED RENEWAL OF THE SHARE PURCHASE MANDATE

The Chairman informed that Resolution 7 is to seek shareholders' approval for the proposed renewal of the Share Purchase Mandate to allow the Company to purchase its issued ordinary shares in the capital of the Company. The Share Purchase Mandate would authorise the purchases or acquisitions of shares up to 10% limit during the period. Shareholders should note that purchases or acquisitions of shares pursuant to the Share Purchase Mandate will be made only as and when the Directors consider it to be in the best interests of the Company and its Shareholders.

Helen proposed and Azri seconded the motion to table resolution 7.

The shareholders present were asked whether they had any questions on this item. As there were no questions, the Chairman invited shareholders to cast their votes on Ordinary Resolution 7.

The result of Ordinary Resolution 7 tabled at the Meeting, taken on a poll, was as follows:

Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
3,905,439,990	3,902,049,990	99.91	3,390,000	0.09

Based on the above result, the Chairman declared Ordinary Resolution 7 carried.

It was **RESOLVED** as an ordinary resolution –

That

(a) That for the purposes of Sections 76C and 76E of the Companies Act, the Directors of the Company be and are hereby authorised to purchase or otherwise acquire from time to time issued ordinary shares in the capital of the Company (whether by way of market purchases or off-market purchases on an equal access scheme) of up to a maximum of 10% of the issued ordinary share capital of the Company (excluding treasury shares and subsidiary holdings) as at the date of the passing of this Ordinary Resolution at any price which the Directors may determine at their discretion, up to but not exceeding the Maximum Price (defined below), and such purchases and acquisitions of the Shares may be effected by way of:

(i) an on-market share acquisition ("**Market Purchase**") transacted on the SGX-ST through the ready market trading system, through one or more duly licensed stockbrokers or dealers appointed by the Company for such purpose; and/or

(ii) an off-market share acquisition ("**Off-Market Purchase**") pursuant to an equal access scheme(s) available to all shareholders, as may be determined or formulated by the Directors in their discretion, which scheme(s) shall satisfy all the conditions prescribed by the Companies Act, and otherwise be in accordance with all other laws and regulations and rules of the SGX-ST ("**Share Purchase Mandate**");

(b) the authority conferred on the Directors pursuant to the Share Purchase Mandate, unless revoked or varied by the Company in a general meeting, may be exercised by the Directors at any time and from time to time during the period commencing from the date of the passing of this Ordinary Resolution and expiring on the earliest of:

(i) the date on which the next AGM of the Company is held;

(ii) the date by which the next AGM of the Company is required by law to be held; and

(iii) the date on which purchases and acquisitions of Shares pursuant to the Share Purchase Mandate are carried out to the full extent mandated;

(c) in this Ordinary Resolution, the purchase price (excluding brokerage, commission, applicable goods and services tax, stamp duties, clearance fees and other related expenses) to be paid for the Shares will be determined by the Directors for the purposes to effect the purchase or acquisition of Shares. The purchase price to be paid for the Shares pursuant to the Share Purchase Mandate (both Market Purchases

and Off-Market Purchases), excluding related expenses of the purchase or acquisition must not exceed ("**Maximum Price**", in each case below):

(i) in the case of a Market Purchase, 105% of the Average Closing Price of the Shares; and

(ii) in the case of an Off-Market Purchase, 110% of the Average Closing Price of the Shares

For the above purposes:

"**Average Closing Price**" means the average of the last dealt prices of a Share for the 5 consecutive Market Days, as defined in the Letter to Shareholders dated 12 October 2026 (the "**Letter**"), on which the Shares are transacted on the SGX-ST immediately preceding the date of the Market Purchase by the Company or, as the case may be, the date of the making of the offer (pursuant to an Off-Market Purchase), and deemed to be adjusted, in accordance with the Catalist Rules for any corporate action which occurs during the relevant 5-day period and the day of the Share Purchase; and

"**date of the making of the offer**" means the date on which the Company makes an offer for the purchase or acquisition of Shares from shareholders, stating the purchase price (which shall not be more than the Maximum Price calculated on the foregoing basis) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase; and

(d) the Directors and each of them be authorised, empowered to complete and do and execute all such things and acts as they or he may think necessary or expedient to give effect to this Ordinary Resolution, with such modifications thereto (if any) as they or he shall think fit in the interests of the Company.

9. ORDINARY RESOLUTION 8
THE PROPOSED RENEWAL OF THE GENERAL MANDATE FOR INTERESTED PERSON TRANSACTIONS WITH DIGITAL LIFE LINE PTE. LTD.

The Chairman informed that Resolution 8 is to seek shareholders' approval on the Proposed Renewal of the General Mandate for Interested Person Transactions with Digital Life Line Pte. Ltd. ("**DLL**").

The Chairman further informed that he and his associates would abstain from voting on this ordinary resolution in accordance with Rule 914 of the Catalist Rules.

Helen proposed and Azri seconded the motion to table resolution 8.

The shareholders present were asked whether they had any questions on this item. As there were no questions, the Chairman invited shareholders to cast their votes on the resolution.

The result of Ordinary Resolution 8 tabled at the Meeting, taken on a poll, was as follows:

Total number of shares represented by votes for and against the relevant resolution	**FOR**		**AGAINST**	
	Number of shares	**As a percentage of total number of votes for and against the resolution (%)**	**Number of shares**	**As a percentage of total number of votes for and against the resolution (%)**
1,444,985,800	1,441,420,800	99.75	3,565,000	0.25

Based on the above result, the Chairman declared Ordinary Resolution 8 carried.

It was **RESOLVED** as an ordinary resolution –

THAT:

(a) approval be and is hereby given, for the purposes of Chapter 9 of the Catalist Rules, for the renewal of the general mandate for the interested person transactions ("**IPT General Mandate I**") as described in the Letter for the EAR Group I (as defined in the Letter) or any of the entities in the EAR Group I, to enter into any transaction falling within the categories of the Mandated Transactions I (as defined in the Letter) set out under IPT General Mandate I, provided that such transactions are made on normal commercial terms and is not prejudicial to the interests of the Company and its minority Shareholders, and in accordance with the review procedures for such interested person transactions as set out in the Letter;

(b) the approval given for the IPT General Mandate I shall, unless revoked or varied by the Company in general meeting, continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is the earlier date; and

(c) the Directors of the Company and/or any of them be and is hereby authorised to enter into all such transactions, arrangements and agreements and approve, execute and deliver all documents and do all deeds and things as may be necessary, expedient, incidental or in the interests of the Company to give effect to the IPT General Mandate I as they and/or any of them may deem fit.

10. ORDINARY RESOLUTION 9
THE PROPOSED RENEWAL OF GENERAL MANDATE FOR INTERESTED PERSON TRANSACTIONS WITH FA SYSTEMS AUTOMATION (S) PTE. LTD.

The Chairman informed that the last agenda is to seek shareholders' approval on the Proposed Renewal of the General Mandate for Interested Person Transactions with FA Systems Automation (S) Pte. Ltd. ("**FA**").

The Chairman further informed that he and his associates would abstain from voting on this ordinary resolution in accordance with Rule 914 of the Catalist Rules.

Azri proposed and Helen seconded the motion to table resolution 9.

The shareholders present were asked whether they had any questions on this item. As there were no questions, the Chairman invited shareholders to cast their votes on the resolution.

The result of Ordinary Resolution 9 tabled at the Meeting, taken on a poll, was as follows:

Total number of shares represented by votes for and against the relevant resolution	**FOR**		**AGAINST**	
	Number of shares	**As a percentage of total number of votes for and against the resolution (%)**	**Number of shares**	**As a percentage of total number of votes for and against the resolution (%)**
1,444,810,800	1,441,420,800	99.77	3,390,000	0.23

Based on the above result, the Chairman declared Ordinary Resolution 9 carried.

It was **RESOLVED** as an ordinary resolution –

THAT:

(a) approval be and is hereby given, for the purposes of Chapter 9 of the Catalist Rules, for the renewal of the general mandate for the interested person transactions ("**IPT General Mandate II**") as described in the Letter for the EAR Group II (as defined in the Letter) or any of the entities in the EAR Group II, to enter into any transaction falling within the categories of the Mandated Transactions II (as defined in the Letter) set out under IPT General Mandate II, provided that such transactions are made on normal commercial terms and is not prejudicial to the interests of the Company and its minority Shareholders, and in accordance with the review procedures for such interested person transactions as set out in the Letter;

(b) the approval given for the IPT General Mandate II shall, unless revoked or varied by the Company in general meeting, continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is the earlier date; and

(c) the Directors of the Company and/or any of them be and is hereby authorised to enter into all such transactions, arrangements and agreements and approve, execute and deliver all documents and do all deeds and things as may be necessary, expedient, incidental or in the interests of the Company to give effect to the IPT General Mandate II as they and/or any of them may deem fit.

V. PRESENTATION BY THE EXECUTIVE CHAIRMAN, MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

The Chairman proceeded to give a presentation on the overview of the Company's business models to the shareholders. The presentation slides had been released on SGXNet before trading hours on 27 October 2026 and a copy of the presentation slides is annexed to this minutes as "**Annexure A**".

The Chairman explained that the Company's serialized radio frequency identification ("**RFID**") technology had evolved since its inception whilst remaining its focuses on improving inventory accuracy, reducing expiry-related wastage, and preventing fraudulent returns through item-level traceability. The Company has been prioritizing its marketing of the 3S Smart Barcode to the big retailers in the United States and had so far gained good commercial traction. It is noted that because the 3S Smart Barcode is a purely digital solution, it eliminates the need for physical inventory, thereby removing warehousing costs and related overheads. The inventory comprises digital barcodes that do not require physical storage space. The Chairman further clarified that the business model is transaction-based rather than licensing-based, with the Company selling customized barcodes directly rather than licensing the underlying software. The Chairman added that fraudulent returns of goods and the "no-questions-asked" return policy in the United States created business opportunities for the Group. With the implementation of the 3S Smart Barcode, the Company will be able to earn a portion from retailers' savings through the successful prevention of fraudulent returns.

The Chairman then presented to shareholders on the affiliation programme initiated through Advanced Digital Healthcare Pte. Ltd. which aims at expanding osteoarthritis care access through partnerships with general practitioners and their clinics. This affiliation programme unlocks revenue opportunities for the Group, including the supply of hyaluronic acid products and supplements, the provision of programme-related services such as therapy equipment, artificial intelligence ("**AI**")-assisted technology support, as well as clinical support comprising resources, operational training and osteoarthritis care solutions. The Chairman informed that this business model mitigates the Group's capital and financial exposure by avoiding the infrastructure costs of establishing its own medical facilities, choosing instead to strategically leverage on the networks of existing general practitioner clinics. In response to Shareholder 2's query regarding whether the Company's AI technology could be easily replicated by competitors, Mr. Low noted that while technology can be emulated, patient loyalty is usually driven by established relationships and familiarity with healthcare providers, which serves as a key competitive moat for the Company's business model.

The Chairman then briefed shareholders on the Mobile Imaging Device for Anterior Segment ("**MIDAS**"), a handheld device designed for point-of-care cataract screening. The Chairman informed that the clinical validation for the device was successfully completed in December 2025, and the Company expects to obtain Class B regulatory approval from the Health Sciences Authority of Singapore in the fourth quarter of 2026.

The Chairman explained that both the osteoarthritis affiliation programme and the portable MIDAS cataract screening device are strategically designed to decentralise healthcare delivery. By equipping neighborhood general practitioners with specialized clinical training and advanced point-of-care technology, the Company is effectively shifting essential medical services away from high-cost tertiary hospitals and directly into local communities. This approach drastically improves healthcare accessibility and affordability for patients, particularly supporting early intervention for Singapore's aging population. Concurring with this view, Mr. Lim noted that the two (2) business models demonstrate the Company's commitment to community care initiatives.

VI. CONCLUSION

The shareholders present were asked whether they had any other questions. As there were no questions and no other business, the Chairman declared the AGM closed. The Chairman thanked those present for their attendance at the AGM.

Confirmed as a true record of the proceedings of
The Annual General Meeting of the Company

Signed

_____

Mr. Chng Weng Wah
Chairman of the Meeting

Date: 19 November 2026

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms. Lee Khai Yinn (Registered Professional, SAC Capital Private Limited)
Address: 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.
Telephone number: +65 6232 3210